Substance Abuse, Substance Use Disorders
Conditions
Brief summary
The purpose of this study is to examine the barriers, facilitators, and optimal processes for implementing a digitally enhanced screening, brief intervention, and referral to treatment (SBIRT) model for Substance Use Disorder SUD treatment among Mayo primary care clinics.
Interventions
BEHAVIORALSenyo App
Subjects will engage with the Senyo Health platform for 12 weeks to deliver Integrated Behavioral Healthcare (IBH) treatment. The Senyo Health platform consists of asynchronous cognitive behavioral therapy modules and weekly check-ins with the IBH care manager. Subjects will also complete a monthly urine test for substances, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete weekly questionnaires.
BEHAVIORALFollow-up
Subjects will have monthly check-in meetings with the Integrated Behavioral Healthcare manager, complete monthly urine tests for substance use, the Timeline Follow Back (TLFB) to gather substance abuse history, and complete monthly questionnaires.
Sponsors
Mayo Clinic
Agency for Healthcare Research and Quality (AHRQ)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to read, write, and understand English * Minimum DAST (1+), audit-C score (3+) * Access and willingness to use a mobile device for asynchronous (text) and synchronous (video) engagement with care. * Access to or willingness to obtain a Primary care provider at a participating Mayo Clinic site; * Eligibility determined by ASAM Assessment
Exclusion criteria
* Diagnosed personality pathology as the primary presenting concern based on clinical judgment, severe cognitive impairment (e.g., intellectual disability or dementia), or psychosis * Inability to actively participate in and learn from psychotherapeutic interaction based on clinical evaluation and clinical judgment * Needing a higher level of mental health care as demonstrated by ASAM32 assessment. * Decline to answer suicidality questions. * Already admitted into or about to initiate treatment in another addiction treatment program. Currently attending High School.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brief Substance Craving Scale (BSCS) | Baseline, weekly for 12 weeks, 4 months, 5 months, 6 months | The Brief Substance Craving Scale is a 16 item, self-report instrument that assesses craving for substances of abuse over a 24 hour period. Intensity and frequency of craving are recorded on a five-point Likert scale, with 0 = Not at all, 1 = Slight, 2 = Moderate, 3 = Considerable, and 4 = Extreme. |
| Timeline Follow Back | Baseline, weekly for 12 weeks, 4 months, 5 months, 6 months | Timeline Follow Back is an assessment to document substance use over a specific period of time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Generalized Anxiety Disorder-7 (GAD-7) | Baseline, weekly for 12 weeks, 4 months, 5 months, 6 months | The General Anxiety Disorder 7-item (GAD 7) scale to assess severity of generalized anxiety disorder. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score for the seven items ranges from 0 to 21 where 0 is no anxiety, 1-4 is minimal anxiety, 5-9 is mild anxiety, 10-14 is moderate anxiety, and 15-21 is severe anxiety. |
| Patient Health Questionnaire-9 (PHQ-9) | Baseline, weekly for 12 weeks, 4 months, 5 months, 6 months | The Patient Health Questionnaire 9-item (PHQ-9) scale used to assess severity of depression. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score ranges from 0 to 27 where 0 is no depression, 1-4 is minimal depression, 5-9 is mild depression, 10-14 is moderate depression, and 15-19 is moderately severe depression and 20-27 severe depression. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORTyler Oesterle
Mayo Clinic
Outcome results
None listed